Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study.
Fingolimod is a an oral disease modifying drug for relapsing remitting multiple sclerosis (MS) preventing egress of B and T cells from lymph nodes. Relevant first dose adverse events include bradycardia and atrioventricular conduction slowing. Cardiac side effects of fingolimod and combinational pharmacotherapy including duloxetine and tolterodine were monitored in mice of different age using implantable ECG telemetric systems. Cardiac tissue was assessed for S1P-receptor subtype (1 and 3), and for GIRK1 expression. Fingolimod led to a significant heart rate reduction within 60 min, which returned to baseline values within 24 h. In older mice bradycardia was more pronounced compared to younger mice. Atrioventricular conduction was not affected. Older mice showed a higher S1PR3 expression in a naïve state and receptor expression was reduced after fingolimod administration. Combination with duloxetine or tolterodine alleviated fingolimod induced heart rate decrease. Our data provide preclinical evidence that negative chronotropic effects of fingolimod might be age dependent, possibly due to an altered expression and internalization of cardiac S1PR3 in older animals. This data could be relevant for future clinical monitoring and patient selection in the aging MS population. Combinational therapies of fingolimod and duloxetine or tolterodine are well tolerated and safe without an increased risk for pronounced bradycardia or arrhythmia.
Department of Neurology, University Hospital Cologne, Cologne, Germany.|Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
Christian
C
Ritter
Department of Neurology, University Hospital Cologne, Cologne, Germany.|Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
Martin K R
MK
Svačina
Department of Neurology, University Hospital Cologne, Cologne, Germany.|Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
Ilja
I
Bobylev
Department of Neurology, University Hospital Cologne, Cologne, Germany.|Center for Molecular Medicine Cologne (CMMC), Cologne, Germany.
Abhijeet
A
Joshi
Department of Physiology, University of Cologne, Cologne, Germany.
Toni
T
Schneider
Department of Neurology, University Hospital Cologne, Cologne, Germany. helmar.lehmann@uk-koeln.de.|Center for Molecular Medicine Cologne (CMMC), Cologne, Germany. helmar.lehmann@uk-koeln.de.
Helmar C
HC
Lehmann
D000375:Aging / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D000818:Animals; D001919:Bradycardia / Q000139:chemically induced* / Q000276:immunology / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004359:Drug Therapy, Combination; D005260:Female; D000068876:Fingolimod Hydrochloride / Q000008:administration & dosage* / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000008:administration & dosage* / Q000009:adverse effects*; D051379:Mice; D008810:Mice, Inbred C57BL; D013686:Telemetry / Q000379:methods
D007166:Immunosuppressive Agents; D000068876:Fingolimod Hydrochloride
Adverse effect; Aging; Immunomodulatory treatment; Multiple sclerosis